These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37352723)

  • 21. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
    Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
    Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains.
    Starr TN; Greaney AJ; Stewart CM; Walls AC; Hannon WW; Veesler D; Bloom JD
    PLoS Pathog; 2022 Nov; 18(11):e1010951. PubMed ID: 36399443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
    Verkhivker G
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein.
    Chakraborty C; Bhattacharya M; Sharma AR; Mallik B
    Int J Biol Macromol; 2022 Oct; 219():980-997. PubMed ID: 35952818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2.
    Philip AM; Ahmed WS; Biswas KH
    Comput Struct Biotechnol J; 2023; 21():1966-1977. PubMed ID: 36936816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of the interaction between the receptor-binding domain of SARS-CoV-2 Omicron (B.1.1.529) variant and human angiotensin-converting enzyme 2.
    Antony P; Jobe A; Vijayan R
    PeerJ; 2022; 10():e13680. PubMed ID: 35811809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omicron variant receptor-binding domain phylogenetics and molecular dynamics.
    Kandeel M; El-Deeb W
    Comput Biol Med; 2022 Jul; 146():105633. PubMed ID: 35605487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico study of SARS-CoV-2 spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron subvariants.
    Abeywardhana S; Premathilaka M; Bandaranayake U; Perera D; Peiris LDC
    J Med Virol; 2023 Jan; 95(1):e28406. PubMed ID: 36519577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of the binding and dynamic features of A.30 variant revealed higher binding of RBD for hACE2 and escapes the neutralizing antibody: A molecular simulation approach.
    Shafiq A; Zubair F; Ambreen A; Suleman M; Yousafi Q; Rasul Niazi Z; Anwar Z; Khan A; Mohammad A; Wei DQ
    Comput Biol Med; 2022 Jul; 146():105574. PubMed ID: 35533461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis for mouse receptor recognition by SARS-CoV-2 omicron variant.
    Zhang W; Shi K; Geng Q; Ye G; Aihara H; Li F
    Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2206509119. PubMed ID: 36256797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution.
    Moulana A; Dupic T; Phillips AM; Chang J; Roffler AA; Greaney AJ; Starr TN; Bloom JD; Desai MM
    Elife; 2023 Feb; 12():. PubMed ID: 36803543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor.
    Zhang Y; He X; Zhai J; Ji B; Man VH; Wang J
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2.
    Golcuk M; Yildiz A; Gur M
    J Mol Graph Model; 2022 Dec; 117():108286. PubMed ID: 35964366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 Omicron variant.
    Bayani F; Safaei Hashkavaei N; Uversky VN; Mozaffari-Jovin S; Sefidbakht Y
    Comput Biol Med; 2022 Aug; 147():105735. PubMed ID: 35767919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
    Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
    Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes.
    Sun Z; Wang L; Li L; Sun Y; Zhang D; Zhou S; Li Y; Li X; Qiao H; Cui Q; Lan Z; Meng X; Xu J; Geng Y; Dai Y
    J Struct Biol; 2023 Sep; 215(3):107996. PubMed ID: 37419228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility.
    Boer JC; Pan Q; Holien JK; Nguyen TB; Ascher DB; Plebanski M
    Front Immunol; 2022; 13():954435. PubMed ID: 36569921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.